Navigation Links
Updated Survival Data from Study Comparing TTF™ (Tumor Treating Fields) Therapy to Best Standard Chemotherapy for Recurrent Glioblastoma Reported at the 16th Annual Scientific Meeting of the Society for NeuroOncology
Date:11/21/2011

e are encouraged by our findings that TTF therapy will find a critical role in the treatment of patients with recurrent GBM."

"The results of this long term follow up continue to validate the promise that NovoTTF™ therapy provides to the thousands of patients who suffer from recurrent GBM," said Asaf Danziger, CEO of Novocure. "We will continue to investigate the potential of this innovative treatment in other types of solid tumor cancers and look forward to sharing our results with the medical community in the future."

About Glioblastoma

Glioblastoma multiforme (GBM) is the most aggressive and most common form of primary brain tumor in the U.S. The disease affects approximately 10,000 Americans each year. The median overall survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment. The disease is widely recognized as one of the most aggressive and deadly forms of cancer.

About the NovoTTF-100A System™

NovoTTF-100A System™ is a portable, non-invasive medical device designed for continuous use throughout the day by the patient. The device has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division. In patients with recurrent glioblastoma brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life without many of the side effects of chemotherapy. The NovoTTF-100A has received marketing approval in the US and is
'/>"/>

SOURCE Novocure
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DEXILANT (dexlansoprazole) Product Information Updated Regarding Coadministration with Plavix (clopidogrel bisulfate)
2. K-V Pharmaceutical Announces Updated Makena® Performance Metrics
3. Updated Hepatitis C Practice Guidelines Now Available from AASLD
4. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
5. Updated: Teikoku Pharma USA, Inc. and Verde Environmental Technologies, Inc. Announce Licensing Agreement for Pharmaceutical Disposal Technology
6. Questcor Provides Updated New Paid Prescription Trends
7. Cepheid Announces Release of Updated Xpert BCR-ABL Monitor Test
8. Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
9. Neuro Kinetics Releases Updated Version of Neuro-Otologic Control and Analysis Software
10. FDA Approves Updated, Clarified Indication for Use for iFuse Implant System®
11. TPI Business and Development Profile Updated on OneMedDatabase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary focus on ... Rajesh C. Shrotriya , MD, Chairman and Chief Executive ... Directors.  The appointment was made in connection with the ...
(Date:9/23/2014)...  As physicians seek information about drugs today, ... learn about new therapies or ask questions of ... report by global sales and marketing consultants at ... a customized mix of digital media and visits ... engage with physicians. And, productive engagement with physicians ...
(Date:9/23/2014)... 23, 2014 Avillion LLP, ... appointment of Jarrod Longcor as Chief ... responsible for structuring, negotiating and executing successful strategic ... as providing management and strategic leadership to the ... leadership team. Mr Longcor brings to ...
Breaking Medicine Technology:CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5Avillion Appoints Jarrod Longcor as Chief Business Officer 2
... Mont., May 8, 2012  Bacterin International Holdings, Inc. ... in the development of revolutionary bone graft material ... third national GPO contract, a three-year agreement with ... and contracting company.  The agreement provides Bacterin,s full ...
... Heska Corporation (NASDAQ: HSKA ), a provider ... announced that its Board of Directors has declared a cash ... payment will be distributed on July 10, 2012 to stockholders ... to pay a regular quarterly dividend of $0.10 per share ...
Cached Medicine Technology:Bacterin International Signs Its Third National GPO Contract with Novation 2Bacterin International Signs Its Third National GPO Contract with Novation 3Bacterin International Signs Its Third National GPO Contract with Novation 4Heska Announces Quarterly Dividend of $0.10 Per Share 2
(Date:9/23/2014)... 2014 Airbus Helicopters Inc. (AHI) is ... as the 2014 Vision Zero Aviation Safety Award ... database, a free flight safety service the company provides ... - Air Medical Specialist for Airbus Helicopters Inc., presented ... check during the Air Medical Transport Conference Annual Community ...
(Date:9/23/2014)... has been shown to be a driving force ... often develops due to chronic inflammation caused by ... has relatively few effective treatment options. Now, scientists ... demonstrated for the first time in preclinical studies ... as astrocyte elevated gene-1 (AEG-1) halts the development ...
(Date:9/23/2014)... York, NY (PRWEB) September 23, 2014 ... that it has entered into a contract to provide ... system to Elderplan, Inc., one of New York City’s ... MJHS, will deploy the eCaring system to help enhance ... , “For nearly 30 years, Elderplan has been ...
(Date:9/23/2014)... EORTC investigators will present the results of their ... 2014 in Madrid. , Joint Symposium: ESMO-ASCO: ... Monday, September 29, 11:00 AM - 12:30 PM, ... Molecular Screening Platforms support new forms of cancer ... program. , Proffered Paper session: Melanoma and ...
(Date:9/23/2014)... Health has awarded $10.1 million in supplemental funding to ... effects of sex in preclinical and clinical studies. , ... and is a catalyst for considering sex as a ... subjects in preclinical research can obscure key findings related ... progressive approach will result in greater awareness of the ...
Breaking Medicine News(10 mins):Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 3Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 4Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:eCaring Signs Care Management Contract with Elderplan, Inc. 2Health News:EORTC presentations at ESMO 2014 Congress 2Health News:EORTC presentations at ESMO 2014 Congress 3Health News:New supplemental awards apply sex and gender lens to NIH-funded research 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 3
... researchers intrigued, egging them on to unlock the secrets embedded ... comprehend the link between profound experiences and their association with ... of the brain of Christian Nuns, while they recalled divine ... MRI of 15 Canadian nuns to get an insight into ...
... only reverses the arterial dysfunction caused by fatty foods but ... the meal, according to new research from Indiana University. ... are part of a growing focus on the effect food ... as the postprandial state. After a fatty meal, arteries lose ...
... conducted towards pest control have lead to the discovery ... of California, have stated that the newly discovered enzyme ... were initially looking for biological pest controls, might actually ... and other inflammatory diseases. It has been reported that ...
... Americans from the year 2000 have been getting poorer. ... in the October issue of the American Journal of Preventive ... climbing rapidly. The researchers have also reported that this growth ... in severe poverty and that ‘moderate’ poverty has grown in ...
... transfusions of blood products from recovering patients may help reduce ... of a pandemic in// future. ,The researchers say ... who received blood transfusions from people who had recovered had ... from the flu. ,The study, which is a ...
... of the University of Sao Paulo Medical School in Brazil ... getting the best care in case of chronic coronary artery ... to be published in the September edition of the Journal ... to receive their physician-recommended treatment showed a significantly lower incidence ...
Cached Medicine News:Health News:Researchers seek to demystify brain activity during mystical encounters 2Health News:A Serving of Exercise After That Saturated Fat 2Health News:Pest Control research Leads to Pain Control Discovery 2Health News:Pest Control research Leads to Pain Control Discovery 3Health News:Increasing Levels Of Severe Poverty In US Could Jeopardize Public Health 2Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 2Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: